<p>What are the pros, cons, knowns, and unknowns of HCC immunotherapy in liver transplantation? Come discuss with Liver Transplantation Associate Editor Dr. Kymberly Watt. Read the recent HEPATOLOGY article and its editorial here: &nbsp;<a href="https://journals.lww.com/hep/fulltext/9900/check_point_s_and_balances__… />
<a href="https://journals.lww.com/hep/abstract/9900/determining_safe_washout_per…;

<p>12:45-12:55 PM- Presentation</p>

<p>12:55-1:15 PM- Audience Q&amp;A and Discussion</p>

The Ipsen-sponsored TLM Theatre will explore current approaches to the management of Biliary Atresia, highlighting opportunities for further optimization of care and patient outcomes. Prognostic biomarkers and the underlying pathophysiology driving disease progression in Biliary Atresia will also be addressed.<br />
<br />
Industry Supporter:&nbsp;Ipsen Biopharmaceuticals<br />
<br />
&nbsp;

Recognizing the ongoing challenges faced by LGBTQ+ individuals and underrepresented minorities (URMs) in health care, particularly amidst recent shifts in funding, policy, and societal attitudes, this community conversation session aims to address systemic barriers contributing to disparities in health care access and outcomes for these populations. The session highlights specific challenges, such as how changes in funding and policies may impact diversity, equity, and inclusion (DEI) initiatives in academic and health care settings. Strategies to sustain and enhance diverse workforce recruitment despite evolving regulations and restrictions are explored. Panelists also address new challenges facing LGBTQ+ patients and health care practitioners, including barriers to accessing equitable liver care and the broader implications of these obstacles on their health and well-being. By bringing together DEI leaders from academic institutions and frontline health care workers, this conversation seeks to identify practical solutions that ensure ongoing support for LGBTQ+ and URM individuals as both patients and health care practitioners. The ultimate goal is to foster a more inclusive hepatology community where diversity is not only acknowledged but celebrated, ensuring equitable health care delivery and professional opportunities for all. 

This interactive discussion explores the complexities of managing hepatitis B in pregnancy, highlighting the key differences in approaches between Asia and Western countries. Presentation topics include: insights into region-specific guidelines; antiviral therapy options; neonatal immunoprophylaxis strategies; and the influence of cultural and health care system factors on care delivery. By comparing practices across regions, the session provides practical knowledge to optimize outcomes for pregnant women with hepatitis B and their newborns in diverse clinical settings.

Join us for a poster highlight of the top abstracts from the CALD SIG.&nbsp;<br />

This disease state education theater will focus on chronic hepatitis B, covering the standard of care, patient care cascade, and clinical management considerations. Expert insights will be shared through engaging case studies and a dynamic panel discussion.<br />
<br />
Industry Supporter:&nbsp;GSK Medical<br />
&nbsp;

Join us for a symposium on primary biliary cholangitis (PBC) designed to encourage the exchange of ideas between leaders in the field and attendees.<br />
<br />
<br />
Supported by: Intercept<br />
<br />
Organized by: Medscape Education<br />
<br />
<br />
For more information and to register, visit:&nbsp;<a href="https://events.medscapelive.org/website/88442/">https://events.medscape… />
<br />
Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Join us for a poster highlight of the top abstracts from the Public Health/Health Care Delivery (PHHD) SIG.&nbsp;<br />
&nbsp;

Explore hepatocellular carcinoma (HCC) through the lens of living with a chronic disease. From the time of HCC diagnosis, most patients are faced with undergoing lifelong surveillance with regular multiphasic imaging studies and, often, undergoing multiple rounds of treatment including different types of locoregional and systemic therapies. This exacts a substantial toll on quality of life, limits the ability to participate in work and family-related activities, and imposes great symptom, psychological, physical, and financial burdens. Speakers focus on the importance of patients preparing for the long-term trajectory of liver cancer and for physicians to support them in their journey. 

Join us for a product theater on an FDA-approved treatment option for primary biliary cholangitis (PBC). Gain insights into how this therapy may support improved PBC outcomes for the appropriate patients affected by this chronic liver disease.<br />
<br />
Industry Supporter:&nbsp;Gilead Sciences<br />
<br />
&nbsp;